Literature DB >> 8862557

Neutralizing antibodies to Escherichia coli Vero cytotoxin 1 and antibodies to O157 lipopolysaccharide in healthy farm family members and urban residents.

D Reymond1, R P Johnson, M A Karmali, M Petric, M Winkler, S Johnson, K Rahn, S Renwick, J Wilson, R C Clarke, J Spika.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) to detect antibodies to Escherichia coli O157 lipopolysaccharide (LPS) was developed with sera from 63 children with confirmed recent E. coli O157 infection and from 256 age-stratified urban controls. The median ELISA values for control and case sera were 0.05 (interquartile range, 0 to 0.20; mean +/- standard deviation [SD], 0.15 +/- 0.22) and 1.41 (interquartile range, 1.11 to 1.59; mean +/- SD, 1.41 +/- 0.53), respectively (P < 0.001). With a breakpoint of 0.59 (mean ELISA value of the control sera + 2 SDs), the assay had a sensitivity, specificity, and positive and negative predictive values of 95, 94, 80, and 98%, respectively, for recent E. coli O157 infection. The O157 LPS assay and Vero cytotoxin (VT) 1-neutralizing-antibody (NAb) assay were used to compare the relative frequencies of O157 LPS antibodies and VT1-NAbs in an age-stratified urban population from Toronto, Ontario, Canada, and in 216 healthy family members from dairy farm in southern Ontario. The frequency of O157 LPS antibodies was about threefold higher in dairy farm residents (12.5%) than in urban residents (4.7%) (P < 0.01). Similarly, the frequency of VT1-NAbs was about sixfold higher in dairy farm residents (42.0%) than in urban residents (7.7%) (P < 0.001). These findings are consistent with a greater level of exposure of dairy farm residents to VT-producing E. coli (VTEC) strains. The high rate of seropositivity to VT1 in farm residents probably reflects the booster effect of repeated VTEC exposures and argues against a sustained generalized immunosuppressive effect of VT1. Seroepidemiological studies may help in assessing the level of exposure of different populations to VTEC strains.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862557      PMCID: PMC229189          DOI: 10.1128/jcm.34.9.2053-2057.1996

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome.

Authors:  E L Lopez; M Diaz; S Devoto; S Grinstein; M Woloj; B E Murray; E Rubeglio; F Mendilaharzu; M Turco; M Vasquez
Journal:  Pediatr Infect Dis J       Date:  1991-01       Impact factor: 2.129

Review 2.  The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome.

Authors:  P M Griffin; R V Tauxe
Journal:  Epidemiol Rev       Date:  1991       Impact factor: 6.222

3.  Epidemiology of sporadic diarrhea due to verocytotoxin-producing Escherichia coli: a two-year prospective study.

Authors:  C H Pai; N Ahmed; H Lior; W M Johnson; H V Sims; D E Woods
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

4.  Anticytotoxin-neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome.

Authors:  S Ashkenazi; T G Cleary; E Lopez; L K Pickering
Journal:  J Pediatr       Date:  1988-12       Impact factor: 4.406

5.  Serological identification of Escherichia coli O157:H7 infection in haemolytic uraemic syndrome.

Authors:  H Chart; H R Smith; S M Scotland; B Rowe; D V Milford; C M Taylor
Journal:  Lancet       Date:  1991-01-19       Impact factor: 79.321

6.  The serological relationship between Escherichia coli O157 and Yersinia enterocolitica O9 using sera from patients with brucellosis.

Authors:  H Chart; O A Okubadejo; B Rowe
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

7.  Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro.

Authors:  C A Lingwood; H Law; S Richardson; M Petric; J L Brunton; S De Grandis; M Karmali
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

8.  Electrophoretic and immunochemical study of the lipopolysaccharides produced by chemostat-grown Escherichia coli O157.

Authors:  K L Dodds; M B Perry; I J McDonald
Journal:  J Gen Microbiol       Date:  1987-09

9.  Serum antibodies to Escherichia coli serotype O157:H7 in patients with hemolytic uremic syndrome.

Authors:  H Chart; S M Scotland; B Rowe
Journal:  J Clin Microbiol       Date:  1989-02       Impact factor: 5.948

10.  Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: a mechanism for the failure of long-lived antibody response to dysenteric disease.

Authors:  A Cohen; V Madrid-Marina; Z Estrov; M H Freedman; C A Lingwood; H M Dosch
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

View more
  22 in total

1.  Evidence of persisting serum antibodies to Escherichia coli O157 lipopolysaccharide and Verocytotoxin in members of rural communities in England.

Authors:  J Evans; R M Chalmers; H Chart; R L Salmon; S M Kench; T J Coleman; D Meadows; P Morgan-Capner; P Softley; M Sillis; D R Thomas
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro.

Authors:  C Menge; L H Wieler; T Schlapp; G Baljer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  An epidemiological study on Verotoxin-producing Escherichia coli (VTEC) infection among population of northern region of Iran (Mazandaran and Golestan provinces).

Authors:  Mohammad Mehdi Aslani; Saeid Bouzari
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

4.  Comparison of the western blot assay with the neutralizing-antibody and enzyme-linked immunosorbent assays for measuring antibody to verocytotoxin 1.

Authors:  D Reymond; M A Karmali; I Clarke; M Winkler; M Petric
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

5.  Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndrome.

Authors:  Kerstin Ludwig; Volkan Sarkim; Martin Bitzan; Mohamed A Karmali; Christoph Bobrowski; Hans Ruder; Rainer Laufs; Ingo Sobottka; Martin Petric; Helge Karch; Dirk E Müller-Wiefel
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

6.  Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome.

Authors:  K Ludwig; M A Karmali; V Sarkim; C Bobrowski; M Petric; H Karch; D E Müller-Wiefel
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

Review 7.  Diarrheagenic Escherichia coli.

Authors:  J P Nataro; J B Kaper
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

8.  Association of Escherichia coli O157:H7 tir polymorphisms with human infection.

Authors:  James L Bono; James E Keen; Michael L Clawson; Lisa M Durso; Michael P Heaton; William W Laegreid
Journal:  BMC Infect Dis       Date:  2007-08-24       Impact factor: 3.090

9.  Verotoxigenic Escherichia coli (VTEC): a major public health threat in Canada.

Authors:  David L Woodward; Clifford G Clark; Richard A Caldeira; Rafiq Ahmed; Frank G Rodgers
Journal:  Can J Infect Dis       Date:  2002-09

10.  Antibody responses to Escherichia coli O157 and other lipopolysaccharides in healthy children and adults.

Authors:  Armando Navarro; Carlos Eslava; Ulises Hernandez; Jose Luis Navarro-Henze; Magali Aviles; Guadalupe Garcia-de la Torre; Alejandro Cravioto
Journal:  Clin Diagn Lab Immunol       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.